Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

IBM and Swiss Hospital Test New Tool for Diagnosing Cancer

Published: Thursday, October 24, 2013
Last Updated: Thursday, October 24, 2013
Bookmark and Share
The compact and easy-to-use device may help unravel tumor heterogeneity and assist in personalized treatment strategies.

IBM scientists are collaborating with pathologists at the University Hospital Zürich to test a new proto-type tool to accurately diagnose different types of cancer. This work is based on a technology developed by IBM scientists called a microfluidic probe, which slightly resembles the nib of a fountain pen.

A critical step in the diagnosis of cancer is the analysis of a patient's biopsy tissue sample, which sometimes can be as small as a pinhead. Even with such a small sample, pathologists can test for the absence or presence of tumor cells and provide important information pertaining to the course of treatment to doctors.

To analyze samples, pathologists typically stain the tissue sample with liquid reagents. The intensity and distribution of the color stain classify and determine the extent of the disease. While this approach provides insights into the tumor, it is increasingly being realized that significant variations exist within the tumor itself; mapping these variations may help understand the drivers for each tumor, and consequently assist in personalizing treatment strategies.

Based on decades of experience in designing silicon computer chips, IBM scientists have developed an innovative technology called a microfluidic probe which can interact with tissue sections at the micrometer scale to help unravel some of the molecular variations within tumors.

The collaboration between IBM and the University Hospital Zürich puts a strong emphasis on uncovering the heterogeneity of tumors. More specifically, the collaboration focuses on lung cancer, which is one of the most prevalent forms of cancer and has a high mortality rate.

“Pathologists are determined to obtain as much accurate information as possible from markedly small biopsy samples”, said Prof. Dr. Alex Soltermann, a pathologist specializing in lung cancer at the Institute for Surgical Pathology of the University Hospital Zürich. “We hope to introduce new technologies, such as the microfluidic probe, into the clinical molecular pathology diagnostic framework to enable a range of investigations, which were previously thought to be infeasible. If we are successful, the tool will be a driver for personalized medicine, and translate into increased confidence in diagnosis and better detection of predictive cancer markers.”

Privatdozent Dr. Peter Schraml, director of the tissue biobank at the Institute of Surgical Pathology, University Hospital Zürich, said, “In addition to assisting in diagnostics, this tool may provide insight into the biomarker distribution in tumor tissues, which can aid in understanding cancer progression.”

The eight-millimeter-wide, diamond-shaped probe consists in its simplest form of a silicon microfluidic head ending with a small tip bearing two microchannels.

“For about a year we have been testing the probe in our lab, and initial results are very encouraging – we are now developing the technology in the context of important aspects in pathology” said Dr. Govind Kaigala, a scientist at IBM Research – Zurich. “Over the next several months, we will install a prototype device at the hospital and work alongside pathologists.”

The tool which houses the microfluidic probe was recently made significantly more compact and user-friendly and today is roughly the size of a tissue box – it is now at stage where it may assist in studying the distribution of low numbers of cancer cells in biopsied samples.

How does it work?

The probe injects very small volumes of reagents on the tissue surface and then continuously aspirates the reagents to prevent spreading and accumulation. This approach is used to deliver and retrieve reagents locally in selected areas of a tissue section with pinpoint accuracy. This local interaction with the tissue sample helps in mapping the heterogeneity in the tissue.

“We are very excited to partner with IBM on the microfluidic probe technology to develop techniques for its use in the clinical pathology framework – this is a fine example of a translational research that could also help answer some basic science questions” says Prof. Holger Moch, head of the Institute of Surgical Pathology at the University Hospital Zürich.

IBM scientists aspire to eventually partner with a medical equipment manufacturer to license the technology and bring it to market as a tool to assist pathologists in making challenging and critical decisions. The microfluidic probes are designed and manufactured at the Binnig and Rohrer Nanotechnology Center on the campus of IBM Research - Zurich.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
The Light of Fireflies for Medical Diagnostics
EPFL scientists have exploited the light of fireflies in a new method that detects biological molecules without the need for complex devices and high costs.
Could a simple saliva test detect Alzheimer's?
Researchers have presented findings suggesting that a simple, non-invasive diagnostic for Alzheimer's could be within reach.
Cheap Diagnostics with a Portable "Paper Machine"
Scientists have developed a cheap, portable system for point of care diagnostics for a range of infectious diseases, genetic conditions and cancer.
New Variant of Streptococcal Bacteria
Scientists have discovered a new variant of streptococcal bacteria that has contributed to a rise in disease cases in the UK over the last 17 years.
New Insights into “Antenna” of Human Cells
Scientists from the University of Leeds have uncovered the most comprehensive list yet of genes implicated in a group of common inherited diseases.
Discordant NIPT Test Results May Reflect Presence of Maternal Cancer
Results published in Journal of the American Medical Association.
Sperm RNA Test May Improve Evaluation of Male Infertility
To help resolve uncertainty—and guide prospective parents to the right fertility treatments—scientists propose the use of a new kind of fertility test. It involves examining sperm RNA by means of next-generation sequencing.
Optical 'Dog's Nose' Developed to Detect Cancer, Other Diseases
Researchers are using optical spectroscopy to develop a quick, non-invasive “breath test” they believe will have the potential to screen for a variety of diseases, including diabetes, infections and cancers.
Ebola Assays Compared in Head-to-Head Analysis
A newly published study has attempted to rigorously evaluate a few of the assays recently granted Emergency Use Authorization by the US Food and Drug Administration to test for Ebola Zaire virus.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!